世界のジェネリック抗がん剤市場予測2021年-2026年

◆英語タイトル:Generic Oncology Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
◆商品コード:IMA21AP100
◆発行会社(リサーチ会社):IMARC
◆発行日:2021年4月
◆ページ数:132
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD1,499 ⇒換算¥164,890見積依頼/購入/質問フォーム
Five UserUSD1,999 ⇒換算¥219,890見積依頼/購入/質問フォーム
EnterprisewideUSD2,499 ⇒換算¥274,890見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はIMARC社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
IMARC社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、世界のジェネリック抗がん剤市場を調査・分析し、序論、範囲・調査手法、エグゼクティブサマリー、イントロダクション、世界のジェネリック医薬品市場、主要地域市場規模、競争状況、製造プロセス、プロジェクト詳細・規定・費用、ローン・金融援助、プロジェクト経済などを掲載しています。
【レポートの概要】

The global generic oncology drugs market exhibited strong growth during 2015-2020. Generic oncology drugs assist in shrinking, controlling and destroying the cancer cells present in the human body. Furthermore, a few oncology drugs are widely prescribed by doctors to alleviate symptoms, including pain. They share the same active ingredients as the already marketed brand-name cancer care medicine. These drugs can be characterized by a different color or flavor than that of the original drug but their quality, performance, intended use, strength, dosage form and route of administration remain the same. Consequently, these drugs efficiently deliver equivalent clinical benefits and yield the same therapeutic effect as their brand-name counterparts at a lower cost.
The escalating prevalence of cancer is one of the key factors driving the market growth. Owing to various factors including a rapid increase in the number of smokers, sedentary lifestyle and excessive exposure to ultraviolet (UV) rays, the number of cancer cases has experienced a significant rise across the globe. In addition to this, the high costs associated with a full-length cancer treatment have led a majority of the patients to opt for these drugs as they are much more cost-effective as compared to their brand-name counterparts. Moreover, patent expiration of key blockbuster drugs is also a significant factor that is providing a boost to the market growth. Along with this, governments of several countries are undertaking initiatives to promote generic drugs. They are continually engaging in research and development (R&D) activities to reduce healthcare expenses related to cancer treatment, thus making the healthcare facility accessible and affordable for all. Such initiatives are augmenting the introduction of several new generic drugs. Other factors such as rising awareness about the benefits of early cancer diagnosis and growing inclination toward preventive measures are contributing to the market growth. Looking forward, IMARC Group expects the global generic oncology drugs market to reach a value of US$ 46.8 Billion by 2026.

Regional Insights:

North America
Europe
Asia Pacific
Middle East and Africa
Latin America

Amongst these, North America holds the leading position in the market, owing to an increasing number of cancer patients and rising awareness about early cancer diagnosis.

Competitive Landscape:

The competitive landscape of the market has also been analyzed in the report with the detailed profiles of the key players operating in the market.

Key Questions Answered in This Report:

1. What is the market size for the global generic oncology drugs market?
2. What is the global generic oncology drugs market growth?
3. What are the global generic oncology drugs market drivers?
4. What are the key industry trends in the global generic oncology drugs market?
5. What is the impact of COVID-19 on the global generic oncology drugs market?
6. What are the major regions in the global generic oncology drugs market?
7. Who are the key companies/players in the global generic oncology drugs market?

【レポートの目次】

1 Preface
2 Scope and Methodology
2.1 Objectives of the study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Generic Drug Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Region
5.4 Market Forecast
6 Global Generic Oncology Drug Market
6.1 Market Overview
6.2 Market Trends
6.3 Impact of COVID-19
6.4 Top Generic Oncology Drugs
6.5 Price Analysis
6.6 Market Forecast
6.7 SWOT Analysis
6.7.1 Overview
6.7.2 Strengths
6.7.3 Weaknesses
6.7.4 Opportunities
6.7.5 Threats
6.8 Value Chain Analysis
6.8.1 Research and Development
6.8.2 Manufacturing
6.8.3 Marketing
6.8.4 Distribution
6.9 Porter’s Five Forces Analysis
6.9.1 Overview
6.9.2 Bargaining Power of Buyers
6.9.3 Bargaining Power of Suppliers
6.9.4 Degree of Competition
6.9.5 Threat of New Entrants
6.9.6 Threat of Substitutes
6.9.7 Regulations in the Generics Industry
6.10 Key Market Drivers and Success Factors
7 Global Generic Oncology Drug Market: Performance of Key Regions
7.1 North America
7.2 Europe
7.3 Asia Pacific
7.4 Middle East and Africa
7.5 Latin America
8 Global Generic Oncology Drug Market: Competitive Landscape
8.1 Competitive Structure
8.2 Market Breakup by Key Players
8.3 Key Player Profiles
9 Generic Oncology Drug Manufacturing Process
9.1 Product Overview
9.2 Detailed Process Flow (Tablets)
9.3 Detailed Process Flow (Injectable)
9.4 Various Types of Unit Operations Involved
9.5 Mass Balance and Raw Material Requirements
10 Project Details, Requirements and Costs Involved
10.1 Land Requirements and Expenditures
10.2 Construction Requirements and Expenditures
10.3 Plant Machinery
10.4 Machinery Pictures
10.5 Raw Material Requirements and Expenditures
10.6 Packaging Requirements and Expenditures
10.7 Transportation Requirements and Expenditures
10.8 Utility Requirements and Expenditures
10.9 Manpower Requirements and Expenditures
10.10 Other Capital Investments
11 Loans and Financial Assistance
12 Project Economics
12.1 Capital Cost of the Project
12.2 Techno-Economic Parameters
12.3 Product Pricing and Margins Across Various Levels of the Supply Chain
12.4 Taxation and Depreciation
12.5 Income Projections
12.6 Expenditure Projections
12.7 Financial Analysis
12.8 Profit Analysis

Figure 1: Global: Generic Drug Market: Major Drivers and Challenges
Figure 2: Global: Generic Drug Market: Sales Value Trends (in Billion US$), 2015-2020
Figure 3: Global: Generic Drug Market Forecast: Sales Value Trends (in Billion US$), 2021-2026
Figure 4: Global: Generic Drug Market: Breakup by Region (in %), 2020
Figure 5: Global: Generic Oncology Drug Industry Overview
Figure 6: Global: Generic Oncology Drug Market: Sales Value Trends (in Billion US$), 2015-2020
Figure 7: Global: Generic Oncology Drug Market Forecast: Sales Value Trends (in Billion US$), 2021-2026
Figure 8: Global: Generic Oncology Drug Market: Breakup by Region (in %), 2020
Figure 9: Global: Generic Oncology Drug Industry: SWOT Analysis
Figure 10: Global: Generic Oncology Drug Industry: Value Chain Analysis
Figure 11: Global: Generic Oncology Drug Industry: Porter’s Five Forces Analysis
Figure 12: North America: Generic Oncology Drug Market (in Million US$), 2015, 2020 & 2026
Figure 13: Asia Pacific: Generic Oncology Drug Market (in Million US$), 2015, 2020 & 2026
Figure 14: Europe: Generic Oncology Drug Market (in Million US$), 2015, 2020 & 2026
Figure 15: Latin America: Generic Oncology Drug Market (in Million US$), 2015, 2020 & 2026
Figure 16: Middle East and Africa: Generic Oncology Drug Market (in Million US$), 2015, 2020 & 2026
Figure 17: Generic Oncology Drug Industry: Profit Margins at Various Levels of the Supply Chain
Figure 18: Generic Oncology Drug Manufacturing: Production Cost Breakup (in %)
Figure 19: Generic Oncology Drug Manufacturing Plant: Detailed Process Flow
Figure 20: Generic Oncology Drug Manufacturing Process: Conversion Rate of Feedstocks
Figure 21: Generic Oncology Drug Manufacturing Plant: Proposed Plant Layout
Figure 22: Generic Oncology Drug Manufacturing Plant: Breakup of Capital Costs (in %)

Table 1: Global: Generic Drug Market: Key Industry Highlights, 2020 and 2026
Table 2: Global: Generic Drug Market Forecast: Breakup by Region, 2021-2026
Table 3: Global: Generic Oncology Drug Market: Key Industry Highlights, 2020 and 2026
Table 4: Generic Oncology Drug Manufacturing Plant: Costs Related to Land and Site Development (in US$)
Table 5: Generic Oncology Drug Manufacturing Plant: Costs Related to Civil Works (in US$)
Table 6: Generic Oncology Drug Manufacturing Plant: Costs Related to Machinery Unit (in US$)
Table 7: Generic Oncology Drug Manufacturing Plant: Raw Material Requirements
Table 8: Generic Oncology Drug Manufacturing Plant: Costs Related to Salaries and Wages (in US$)
Table 9: Generic Oncology Drug Manufacturing Plant: Costs Related to Other Capital Investments (in US$)
Table 10: Details of Financial Assistance Offered by Financial Institutions
Table 11: Generic Oncology Drug Manufacturing Plant: Capital Costs (in US$)
Table 12: Generic Oncology Drug Manufacturing Plant: Techno-Economic Parameters
Table 13: Generic Oncology Drug Manufacturing Plant: Taxation and Depreciation
Table 14: Generic Oncology Drug Manufacturing Plant: Income Projections (in US$)
Table 15: Generic Oncology Drug Manufacturing Plant: Expenditure Projections (in US$)
Table 16: Generic Oncology Drug Manufacturing Plant: Cash Flow Analysis Without Considering the Income Tax Liability
Table 17: Generic Oncology Drug Manufacturing Plant: Cash Flow Analysis on Considering the Income Tax Liability
Table 18: Generic Oncology Drug Manufacturing Plant: Profit and Loss Account

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のジェネリック抗がん剤市場予測2021年-2026年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆